Macrophage-centered resistance programs in cancer: A unified framework for therapeutic resistance and precision immunotherapy
Drug Resistance Updates · 2027-01 · 90 · 101498
DOI: 10.1016/j.drup.2026.101498 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2027-01. Verfasst von Yanjun Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China. Die Arbeit nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Therapeutic resistance remains a major barrier to durable cancer control despite advances in immunotherapy, targeted therapy, cellular therapies, chemotherapy, and radiotherapy. Although tumor cell-intrinsic genetic and epigenetic alterations are well-established drivers of resistance, treatment outcomes are also shaped by dynamic interactions within the tumor microenvironment (TME). Among its stromal and immune constituents, tumor-associated macrophages (TAMs) are prominent regulators of therapeutic resistance because of their functional plasticity and capacity to integrate diverse environmental signals. Here, we introduce macrophage-centered resistance programs as an integrative framework comprising four recurrent, non-mutually exclusive functional modules: lipid-associated, matrix-remodeling, glyco-immune, and metabolic programs. These modules link tumor-derived stressors to macrophage adaptation, immune suppression, stromal remodeling, and therapeutic persistence, while allowing substantial overlap, context dependence, and dynamic interconversion. We further distinguish associative observations from mechanistic and causal evidence and examine how macrophage-associated resistance mechanisms interact with treatment-specific tumor cell-intrinsic pathways across immune checkpoint blockade, cellular therapy, targeted therapy, chemotherapy, and radiotherapy. Finally, we discuss macrophage-directed therapeutic strategies and the requirements for biomarker-guided precision immunotherapy, including clinical validation, assay standardization, and longitudinal monitoring. This framework is intended as a testable organizational model for understanding macrophage-mediated therapeutic resistance and guiding more precise macrophage-directed interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China.
- The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China. Electronic address: xusuling@nbu.edu.cn.
- Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, China; Health Science Center, Ningbo University, Ningbo, Zhejiang 315010, China.
- Department of Chronic Disease Epidemiology, Yale School of Public Health, School of Medicine, Yale University, New Haven, CT 06510, USA.
- Sanford Stem Cell Institute, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: wma@health.ucsd.edu.
Zitieren
APA
Li, Y., Xu, S., Xie, H., Wang, Q., Lu, L., & Ma, W. (2027). Macrophage-centered resistance programs in cancer: A unified framework for therapeutic resistance and precision immunotherapy. Drug Resistance Updates, 90, 101498. https://doi.org/10.1016/j.drup.2026.101498
Vancouver
Li Y, Xu S, Xie H, Wang Q, Lu L, Ma W. Macrophage-centered resistance programs in cancer: A unified framework for therapeutic resistance and precision immunotherapy. Drug Resistance Updates. 2027;90:101498. doi:10.1016/j.drup.2026.101498
BibTeX
@article{Li2027,
author = {Li, Yanjun and Xu, Suling and Xie, Huangze and Wang, Qingqing and Lu, Lingeng and Ma, Wenxue},
title = {Macrophage-centered resistance programs in cancer: A unified framework for therapeutic resistance and precision immunotherapy},
journal = {Drug Resistance Updates},
year = {2027},
volume = {90},
pages = {101498},
doi = {10.1016/j.drup.2026.101498}
}
EUVIMED